NASDAQ | VICL: 3.90  -0.09
investors
Investors

News Releases

DateSubject
August 9, 2016 Vical Reports Second Quarter 2016 Financial Results
August 2, 2016 Vical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results
August 1, 2016 Vical Announces $7.8 Million Equity Investment by Partner, AnGes MG
June 20, 2016 Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
June 13, 2016 Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference
May 31, 2016 Vical Provides VL-2397 Updates at BIO International Convention
May 9, 2016 Vical Reports First Quarter 2016 Financial Results
May 2, 2016 Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results
March 30, 2016 FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis
March 14, 2016 Vical Reports Fourth Quarter 2015 Financial Results
March 9, 2016 Vical to Present at the 28th Annual ROTH Conference
March 7, 2016 Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2015 Financial Results
March 7, 2016 Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
January 6, 2016 FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis

AnGes Ebola Antibody Therapy

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.